ATE418555T1 - A2a-adenosinrezeptorantagonisten - Google Patents

A2a-adenosinrezeptorantagonisten

Info

Publication number
ATE418555T1
ATE418555T1 AT04759359T AT04759359T ATE418555T1 AT E418555 T1 ATE418555 T1 AT E418555T1 AT 04759359 T AT04759359 T AT 04759359T AT 04759359 T AT04759359 T AT 04759359T AT E418555 T1 ATE418555 T1 AT E418555T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
formula
adenosin
adenosin receptor
antagonists
Prior art date
Application number
AT04759359T
Other languages
English (en)
Inventor
Hairuo Peng
Gang Yao
Chi Vu
Russell C Petter
Gnanasambandam Kumaravel
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE418555T1 publication Critical patent/ATE418555T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT04759359T 2003-04-09 2004-04-09 A2a-adenosinrezeptorantagonisten ATE418555T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46148403P 2003-04-09 2003-04-09

Publications (1)

Publication Number Publication Date
ATE418555T1 true ATE418555T1 (de) 2009-01-15

Family

ID=33299825

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04759359T ATE418555T1 (de) 2003-04-09 2004-04-09 A2a-adenosinrezeptorantagonisten

Country Status (5)

Country Link
US (1) US7834014B2 (de)
EP (1) EP1633756B1 (de)
AT (1) ATE418555T1 (de)
DE (1) DE602004018637D1 (de)
WO (1) WO2004092173A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060106040A1 (en) 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
ATE556712T1 (de) 2005-06-07 2012-05-15 Kyowa Hakko Kirin Co Ltd A2a antagonisten zur behandlung von motorischen störungen
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
EP1939197A1 (de) 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-Ethinylxanthinderivate als selektive Antagonisten des A2A-Rezeptors
EP2188288A1 (de) 2007-09-11 2010-05-26 Abbott Laboratories Octahydropyrrolo[3,4-b]pyrrol-n-oxide
EP2322223A4 (de) * 2008-07-23 2012-08-22 Kyowa Hakko Kirin Co Ltd Therapeutisches mittel gegen migräne
US20130190327A1 (en) 2010-02-26 2013-07-25 Catabasis Pharmaceuticals Inc Bis-fatty acid conjugates and their uses
US9216224B2 (en) 2010-03-05 2015-12-22 Catabasis Pharmaceuticals, Inc. Fatty acid COX inhibitor derivatives and their uses
US20130045939A1 (en) 2010-03-19 2013-02-21 Catabasis Pharmaceuticals, Inc. Fatty acid macrolide derivatives and their uses
AU2013344716B2 (en) 2012-11-16 2018-03-01 University Health Network Pyrazolopyrimidine compounds
WO2014101120A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
MA46092A (fr) 2016-08-31 2021-04-21 Agios Pharmaceuticals Inc Inhibiteurs de processus métaboliques cellulaires
WO2018175906A1 (en) 2017-03-24 2018-09-27 Nanosyn, Inc. Fused triazolo-pyrimidine compounds having useful pharmaceutical application
PT3611174T (pt) * 2017-04-07 2022-07-07 Medshine Discovery Inc Derivado de [1,2,4]triazolo[1,5-c]pirimidina como inibidor do recetor a2a
CN109535161B (zh) * 2017-09-22 2021-09-03 江苏恒瑞医药股份有限公司 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
CR20230030A (es) 2018-02-27 2023-03-10 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b (divisional 2020-0441)
GB201804922D0 (en) * 2018-03-27 2018-05-09 Ucl Business Plc Traatment
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
CA3103068C (en) 2018-06-26 2024-06-25 Zhejiang Vimgreen Pharmaceuticals, Ltd Triazolotriazine derivatives as a2a receptor antagonists
MX2021000116A (es) 2018-07-05 2021-03-29 Incyte Corp Derivados de pirazina fusionados como inhibidores de a2a/a2b.
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2021129843A1 (zh) * 2019-12-26 2021-07-01 浙江春禾医药科技有限公司 三唑并三嗪衍生物在治疗疾病中的用途
KR102863028B1 (ko) * 2021-04-23 2025-09-22 주식회사 종근당 아데노신 A2a 수용체 길항제로서의 화합물 및 이를 포함하는 약학적 조성물
WO2023191400A1 (ko) * 2022-04-01 2023-10-05 에이치케이이노엔 주식회사 에틸 피페리딘 트리아졸로 트리아진 유도체, 이의 제조방법 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7406641A (de) 1973-05-22 1974-11-26
JPS56131587A (en) 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd 7-substituted triazolopyrimidine derivative and its preparation
JPS56131586A (en) 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd Triazolopyrimidine derivative and its preparation
JPS5962595A (ja) 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５，７―トリ置換―トリアゾロピリミジン誘導体
DE3304330A1 (de) 1983-02-09 1984-08-09 Basf Ag, 6700 Ludwigshafen Neue 2h-v-triazolyl(4,5-d)-pyrimidine und deren verwendung
JPS60140335A (ja) 1983-12-28 1985-07-25 Konishiroku Photo Ind Co Ltd 熱現像カラ−感光材料
US5204353A (en) 1987-04-07 1993-04-20 Ciba-Geigy Corporation 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith
WO1990008148A1 (en) 1989-01-23 1990-07-26 Pfizer Inc. Bis-aza-bicyclic anxiolytic agents
ZA902280B (en) 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor agents
ATE128466T1 (de) 1989-04-17 1995-10-15 Bayer Ag Verfahren zur herstellung von 2,7- diazabicyclo(3.3.0)octanen.
HU221200B1 (en) 1990-01-22 2002-08-28 Biochemie Gmbh Process for producing beta-lactames
JPH0436284A (ja) 1990-05-29 1992-02-06 Sumitomo Chem Co Ltd ジフェニルフロピリミジン誘導体、その製造法およびそれを有効成分とする除草剤
GB2244487B (en) 1990-05-29 1994-02-02 Ici Plc Azole derivatives
US5356894A (en) 1990-05-29 1994-10-18 Rodney Peter W Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
CA2100863A1 (en) 1991-01-23 1992-07-24 David A. Bullough Adenosine kinase inhibitors
GB9111130D0 (en) 1991-05-23 1991-07-17 Ici Plc Azole derivatives
ES2284226T3 (es) 1991-07-02 2007-11-01 Nektar Therapeutics Dispositivo para proporcionar medicamentos en aerosol.
HUT70954A (en) 1992-04-03 1995-11-28 Upjohn Co Bicyclic-heterocyclic amines containing nitrogen heteroatoms
US6005109A (en) 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
KR0173172B1 (ko) 1992-12-17 1999-02-01 알렌 제이. 스피겔 Crf 길항제로서의 피롤로피리미딘
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
BR9307659A (pt) 1992-12-17 1999-06-29 Pfizer Pirazóis e pirazolopirimidinas tendo atividade antagonista crf
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
WO1995003806A1 (en) 1993-07-27 1995-02-09 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
US5789407A (en) 1993-09-06 1998-08-04 Kyowa Hakko Kogyo Co., Ltd. Method of treating depression with certain triazine derivatives
PL313973A1 (en) 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
KR100444123B1 (ko) 1995-07-11 2004-10-14 아스트라제네카 악티에볼라그 신규한혈소판응집억제제
US5789416B1 (en) 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
JP4195729B2 (ja) 1997-03-24 2008-12-10 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
CA2294117A1 (en) 1997-07-03 1999-01-14 Dupont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
AU8181098A (en) 1997-07-03 1999-01-25 Du Pont Pharmaceuticals Company Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
US5939432A (en) 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
EP0975345A1 (de) 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine zur blockierung der purinrezeptoren und zur behandlung von bewegung- oder neurodegenerativen erkrankungen
WO1999035147A1 (en) 1998-01-05 1999-07-15 Eisai Co., Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
AU2639299A (en) 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
JPH11279193A (ja) 1998-03-24 1999-10-12 Akira Matsuda アデノシン誘導体
YU76100A (sh) 1998-06-02 2003-12-31 Osi Pharmaceuticals Inc. Pirolo(2,3-d) pirimidin preparati i njihova primena
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
EP1116722B1 (de) 1998-09-22 2005-01-12 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-DERIVATE
TW564247B (en) 1999-04-08 2003-12-01 Akzo Nobel Nv Bicyclic heteraromatic compound
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
ES2246867T3 (es) 1999-07-02 2006-03-01 Eisai Co., Ltd. Compuestos de imidazol condensados y medicamentos contra la diabetes mellitus.
EP1261327B1 (de) 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Adenosin-rezeptor modulatoren
WO2003020723A1 (en) 2001-08-30 2003-03-13 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINE DERIVATIVE
HUP0402324A3 (en) 2001-11-30 2008-09-29 Schering Corp [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine a2a receptor antagonists and pharmaceutical compositions containing them
JPWO2003068776A1 (ja) * 2002-02-15 2005-06-02 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
WO2004029056A1 (ja) * 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. [１，２，４]トリアゾロ[１，５−ｃ]ピリミジン誘導体
EP1615930A2 (de) * 2003-04-09 2006-01-18 Biogen Idec MA, Inc. Als a2a-adenosinrezeptor-antagonisten geeignete triazolotriazine und pyrazolotriazine

Also Published As

Publication number Publication date
EP1633756A2 (de) 2006-03-15
WO2004092173A2 (en) 2004-10-28
HK1083838A1 (en) 2006-07-14
EP1633756B1 (de) 2008-12-24
WO2004092173A3 (en) 2004-12-09
US7834014B2 (en) 2010-11-16
DE602004018637D1 (de) 2009-02-05
US20070173505A1 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
ATE418555T1 (de) A2a-adenosinrezeptorantagonisten
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
MXPA04000886A (es) Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
MXPA05008524A (es) Pirazoles y metodos de elaboracion y uso de los mismos.
NL300933I2 (nl) Letermovir
ATE461196T1 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
MXPA05002442A (es) Imidazolopiridinas y metodos para la elaboracion y uso de las mismas.
ATE424403T1 (de) Polycycloalkylpurine als adenosinrezeptorantagonisten
WO2006015357A3 (en) 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
CY1109764T1 (el) Υποκατεστημενα βενζαζολια και χρηση αυτων ως αναστολεις κινασης raf
WO2005097140A3 (en) Selective antagonists of a2a adenosine receptors
UA81624C2 (ru) Тризамещённые гетероарилы и способ их получения и применение
DOP2002000429A (es) Imidazotriazinas
EA200501333A1 (ru) 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
ATE466860T1 (de) Cgrp-rezeptorantagonisten
DK1450811T3 (da) Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
MXPA03009185A (es) Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson.
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
WO2004092171A3 (en) Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists
ATE403656T1 (de) Xanthinderivate als a2b- adenosinrezeptorantagonisten
TR200301062T2 (tr) Adenosin reseptörü antagonistleri ve bu antagonistlerin yapım ve kullanım yöntemleri
TW200621752A (en) Pyrimidinylpyrazoles and methods of making and using the same
DE60227576D1 (de) 3,6-DISUBSTITUIERTE AZABICYCLO i3.1.0 -HEXANDERIVATIVE ALS ANTAGONISTEN DES MUSCARINREZEPTORS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties